Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPERAR: Darolutamide ± LH-RH agonist in metastatic extramammary Paget's disease
jRCT2031220508Phase 2Completed
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of darolutamide in extramammary Paget disease (EMPD) (2 cohorts). Primary endpoint: Primary: Response rate by central review in patients with ≥10% AR incidence. Started Dec 2022; status: completed.
02
Drugs
darolutamide
03
Conditions
extramammary Paget disease (EMPD)
Beyond the preview
Go deeper on jRCT2031220508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220508.